http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2009007916-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
filingDate 2008-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2be70bd7680630cd6268afa8e98c7854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74a7c47195012e2c3f0fa6f643618e8
publicationDate 2009-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2009007916-A
titleOfInvention PHARMACEUTICAL COMPOSITIONS INCLUDING 3,5-DIAMINO-6- (2,3-DICL OROFENIL) -L, 2,4, -TRIAZINE; OR R (-) - 2,4-DIAMINO-5- (2,3-DICLOROPHENYL) -6-FLUOROMETIL PYRIMIDINE AND A NEUROQUININE RECEIVER 1.
abstract The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at a subtherapeutic dose, as a combined preparation for simultaneous or combined administration, and to the use of said compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
priorityDate 2007-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420772628
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9860692

Total number of triples: 29.